LAVA Therapeutics (NASDAQ:LVTX – Get Free Report)’s stock price was down 2.3% on Friday . The stock traded as low as $2.96 and last traded at $3.03. Approximately 47,453 shares changed hands during trading, a decline of 96% from the average daily volume of 1,352,372 shares. The stock had previously closed at $3.10.
Analysts Set New Price Targets
Separately, HC Wainwright restated a “buy” rating and issued a $6.00 price target on shares of LAVA Therapeutics in a research report on Thursday, March 21st.
Get Our Latest Stock Report on LVTX
LAVA Therapeutics Price Performance
LAVA Therapeutics (NASDAQ:LVTX – Get Free Report) last announced its earnings results on Wednesday, March 20th. The company reported ($0.24) earnings per share for the quarter, missing analysts’ consensus estimates of $0.16 by ($0.40). The business had revenue of $0.35 million during the quarter, compared to analyst estimates of $25.00 million. LAVA Therapeutics had a negative net margin of 620.09% and a negative return on equity of 68.54%. As a group, sell-side analysts anticipate that LAVA Therapeutics will post -1.41 EPS for the current year.
Institutional Trading of LAVA Therapeutics
An institutional investor recently bought a new position in LAVA Therapeutics stock. Pathway Financial Advisors LLC bought a new position in shares of LAVA Therapeutics (NASDAQ:LVTX – Free Report) in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund bought 14,000 shares of the company’s stock, valued at approximately $47,000.
LAVA Therapeutics Company Profile
LAVA Therapeutics N.V., a clinical-stage immuno-oncology company, focuses on developing cancer treatments. The company through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer patients.
Read More
- Five stocks we like better than LAVA Therapeutics
- High Dividend REITs: Are They an Ideal Way to Diversify?
- MarketBeat Week in Review – 4/29 – 5/3
- 3 Healthcare Dividend Stocks to Buy
- Apple’s Earnings Show Investors Its Strength and Its Weakness
- How to Use High Beta Stocks to Maximize Your Investing Profits
- Bargain Alert: 3 Large Caps With Extremely Oversold RSIs
Receive News & Ratings for LAVA Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LAVA Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.